332 related articles for article (PubMed ID: 21321264)
1. In vitro and in vivo evaluation of 64Cu-labeled SarAr-bombesin analogs in gastrin-releasing peptide receptor-expressing prostate cancer.
Lears KA; Ferdani R; Liang K; Zheleznyak A; Andrews R; Sherman CD; Achilefu S; Anderson CJ; Rogers BE
J Nucl Med; 2011 Mar; 52(3):470-7. PubMed ID: 21321264
[TBL] [Abstract][Full Text] [Related]
2. In vitro and in vivo evaluation of a 64Cu-labeled NOTA-Bn-SCN-Aoc-bombesin analogue in gastrin-releasing peptide receptor expressing prostate cancer.
Craft JM; De Silva RA; Lears KA; Andrews R; Liang K; Achilefu S; Rogers BE
Nucl Med Biol; 2012 Jul; 39(5):609-16. PubMed ID: 22261146
[TBL] [Abstract][Full Text] [Related]
3. PET of tumors expressing gastrin-releasing peptide receptor with an 18F-labeled bombesin analog.
Dijkgraaf I; Franssen GM; McBride WJ; D'Souza CA; Laverman P; Smith CJ; Goldenberg DM; Oyen WJ; Boerman OC
J Nucl Med; 2012 Jun; 53(6):947-52. PubMed ID: 22570329
[TBL] [Abstract][Full Text] [Related]
4. MicroPET imaging of a gastrin-releasing peptide receptor-positive tumor in a mouse model of human prostate cancer using a 64Cu-labeled bombesin analogue.
Rogers BE; Bigott HM; McCarthy DW; Della Manna D; Kim J; Sharp TL; Welch MJ
Bioconjug Chem; 2003; 14(4):756-63. PubMed ID: 12862428
[TBL] [Abstract][Full Text] [Related]
5. microPET and autoradiographic imaging of GRP receptor expression with 64Cu-DOTA-[Lys3]bombesin in human prostate adenocarcinoma xenografts.
Chen X; Park R; Hou Y; Tohme M; Shahinian AH; Bading JR; Conti PS
J Nucl Med; 2004 Aug; 45(8):1390-7. PubMed ID: 15299066
[TBL] [Abstract][Full Text] [Related]
6. N-terminal modifications improve the receptor affinity and pharmacokinetics of radiolabeled peptidic gastrin-releasing peptide receptor antagonists: examples of 68Ga- and 64Cu-labeled peptides for PET imaging.
Gourni E; Mansi R; Jamous M; Waser B; Smerling C; Burian A; Buchegger F; Reubi JC; Maecke HR
J Nucl Med; 2014 Oct; 55(10):1719-25. PubMed ID: 25146125
[TBL] [Abstract][Full Text] [Related]
7. Theranostic Perspectives in Prostate Cancer with the Gastrin-Releasing Peptide Receptor Antagonist NeoBOMB1: Preclinical and First Clinical Results.
Nock BA; Kaloudi A; Lymperis E; Giarika A; Kulkarni HR; Klette I; Singh A; Krenning EP; de Jong M; Maina T; Baum RP
J Nucl Med; 2017 Jan; 58(1):75-80. PubMed ID: 27493272
[TBL] [Abstract][Full Text] [Related]
8. Small-animal PET of tumors with (64)Cu-labeled RGD-bombesin heterodimer.
Liu Z; Li ZB; Cao Q; Liu S; Wang F; Chen X
J Nucl Med; 2009 Jul; 50(7):1168-77. PubMed ID: 19525469
[TBL] [Abstract][Full Text] [Related]
9. In vivo evaluation and small-animal PET/CT of a prostate cancer mouse model using 64Cu bombesin analogs: side-by-side comparison of the CB-TE2A and DOTA chelation systems.
Garrison JC; Rold TL; Sieckman GL; Figueroa SD; Volkert WA; Jurisson SS; Hoffman TJ
J Nucl Med; 2007 Aug; 48(8):1327-37. PubMed ID: 17631556
[TBL] [Abstract][Full Text] [Related]
10. 18F-labeled bombesin analogs for targeting GRP receptor-expressing prostate cancer.
Zhang X; Cai W; Cao F; Schreibmann E; Wu Y; Wu JC; Xing L; Chen X
J Nucl Med; 2006 Mar; 47(3):492-501. PubMed ID: 16513619
[TBL] [Abstract][Full Text] [Related]
11. A new (68)Ga-labeled BBN peptide with a hydrophilic linker for GRPR-targeted tumor imaging.
Pan D; Xu YP; Yang RH; Wang L; Chen F; Luo S; Yang M; Yan Y
Amino Acids; 2014 Jun; 46(6):1481-9. PubMed ID: 24633452
[TBL] [Abstract][Full Text] [Related]
12. Molecular imaging of gastrin-releasing peptide receptor-positive tumors in mice using 64Cu- and 86Y-DOTA-(Pro1,Tyr4)-bombesin(1-14).
Biddlecombe GB; Rogers BE; de Visser M; Parry JJ; de Jong M; Erion JL; Lewis JS
Bioconjug Chem; 2007; 18(3):724-30. PubMed ID: 17378600
[TBL] [Abstract][Full Text] [Related]
13. Radiochemical investigations of 177Lu-DOTA-8-Aoc-BBN[7-14]NH2: an in vitro/in vivo assessment of the targeting ability of this new radiopharmaceutical for PC-3 human prostate cancer cells.
Smith CJ; Gali H; Sieckman GL; Hayes DL; Owen NK; Mazuru DG; Volkert WA; Hoffman TJ
Nucl Med Biol; 2003 Feb; 30(2):101-9. PubMed ID: 12623108
[TBL] [Abstract][Full Text] [Related]
14. Dual-Modality Imaging of Prostate Cancer with a Fluorescent and Radiogallium-Labeled Gastrin-Releasing Peptide Receptor Antagonist.
Zhang H; Desai P; Koike Y; Houghton J; Carlin S; Tandon N; Touijer K; Weber WA
J Nucl Med; 2017 Jan; 58(1):29-35. PubMed ID: 27516447
[TBL] [Abstract][Full Text] [Related]
15. The effect of macrocyclic chelators on the targeting properties of the 68Ga-labeled gastrin releasing peptide receptor antagonist PEG2-RM26.
Varasteh Z; Mitran B; Rosenström U; Velikyan I; Rosestedt M; Lindeberg G; Sörensen J; Larhed M; Tolmachev V; Orlova A
Nucl Med Biol; 2015 May; 42(5):446-454. PubMed ID: 25684649
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and radiopharmacological evaluation of ⁶⁴Cu-labeled bombesin analogs featuring a bis(2-pyridylmethyl)-1,4,7-triazacyclononane chelator.
Bergmann R; Ruffani A; Graham B; Spiccia L; Steinbach J; Pietzsch J; Stephan H
Eur J Med Chem; 2013; 70():434-46. PubMed ID: 24184988
[TBL] [Abstract][Full Text] [Related]
17. Receptor-binding, biodistribution, dosimetry, and micro-SPECT/CT imaging of 111In-[DTPA(1), Lys(3), Tyr(4)]-bombesin analog in human prostate tumor-bearing mice.
Ho CL; Chen LC; Lee WC; Chiu SP; Hsu WC; Wu YH; Yeh CH; Stabin MG; Jan ML; Lin WJ; Lee TW; Chang CH
Cancer Biother Radiopharm; 2009 Aug; 24(4):435-43. PubMed ID: 19694578
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
